Physician profile
Carrie Kitko
NPI 1205912177
$50,598.70
in general payments reported to CMS, 2019-2025
18 companies · $18K in 2025
The $18K reported for 2025 was more than what 90% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $163 · 2021: $4,755 · 2022: $73.82 · 2023: $7,436 · 2024: $20K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $38K · Travel and Lodging: $2,995 · Food and Beverage: $2,144 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,972.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $37,937.00 |
| Travel and Lodging | $2,995.37 |
| Food and Beverage | $2,143.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,972.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $16,407.04 | 2023-2025 | Niktimvo, Jakafi |
| Sanofi-Aventis U.S. LLC | $12,824.19 | 2023-2025 | |
| Csl Behring | $10,200.00 | 2024-2025 | |
| Horizon Therapeutics Plc | $4,650.00 | 2021 | |
| Mesoblast, INC. | $3,125.00 | 2025 | Ryoncil |
| Adaptive Biotechnologies Corporation | $1,892.84 | 2023-2025 | Clonoseq |
| Novartis Pharmaceuticals Corporation | $507.25 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $491.13 | 2019-2023 | |
| Kite Pharma, INC. | $187.06 | 2019-2020 | |
| Syndax Pharmaceuticals, INC. | $135.15 | 2025 | |
| Kadmon Pharmaceuticals LLC | $105.22 | 2021 | |
| Genzyme Corporation | $73.82 | 2022 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carrie Kitko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.